Bladder cancer
INACTIVE --- New hope for patients progressing after first-line treatment for mUCa

David (81 years old)

David is an 81-year-old retired firefighter. Every month he meets up with his ex-colleagues for a game of cards and a walk down memory lane.

He was diagnosed with UCa of the bladder with metastases to the liver. He was cisplatin-ineligible due to an impaired GFR. His tumour was strongly positive for PD-L1. He started pembrolizumab. Now, 18 months after initiation of pembrolizumab, he has a follow-up visit.

Assessment summary:

  • ECOG PS: 1
  • Peripheral neuropathy grade I
  • GFR: 45 ml/min
  • CT scan: new liver lesions
  • FGFR2/3 mutation status in diagnostic biopsy specimen: activating FGFR3 gene fusion

Which treatment option would you choose for this patient?